https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
administrator
max-mobility-/-permobil-issues-nationwide-recall-of-smartdrive-speed-control-dial-due-to-the-motor-being-unresponsive-to-the-user FDA
  • January 17, 2025

Max Mobility / Permobil Issues Nationwide Recall of SmartDrive Speed Control Dial Due to the Motor Being Unresponsive to the User

Max Mobility/Permobil has initiated a nationwide recall of the Speed Control Dial component used with the SmartDrive MX2+ Power Assist…
health-fraud-scams Drug Test
  • January 17, 2025

Health Fraud Scams

Learn how to spot health fraud and avoid it.
information-about-mifepristone-for-medical-termination-of-pregnancy-through-ten-weeks-gestation Drug Test
  • January 17, 2025

Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation

Mifeprex (mifepristone) Information
artificial-intelligence-for-drug-development Drug Test
  • January 17, 2025

Artificial Intelligence for Drug Development

FDA recognizes the increased use of AI throughout the drug development process and across a range of therapeutic areas. Learn…
homeopathic-products Drug Test
  • January 17, 2025

Homeopathic Products

Homeopathy is an alternative medical practice that was developed in the late 1700s.
oncology-(cancer)/hematologic-malignancies-approval-notifications Drug Test
  • January 17, 2025

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer…
fda-approves-zanubrutinib-for-waldenstrom’s-macroglobulinemia Drug Test
  • January 17, 2025

FDA approves zanubrutinib for Waldenström’s macroglobulinemia

Oncology News burst
what’s-new-related-to-drugs Drug Test
  • January 17, 2025

What’s New Related to Drugs

Want to know what’s new on drugs from FDA? This page provides quick links to the latest on a variety…
fda-approves-datopotamab-deruxtecan-dlnk-for-unresectable-or-metastatic,-hr-positive,-her2-negative-breast-cancer Drug Test
  • January 17, 2025

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and…
fda-disco.-burst-edition:-fda-approval-of-ryoncil-(remestemcel-l-rknd)-for-steroid-refractory-acute-graft-versus-host-disease-in-pediatric-patients Drug Test
  • January 17, 2025

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

Listen to a soundcast of the 12.18.2024 FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in…